Peptide·plain sequence-like

Bivalirudin

ATLPC0035832

FPRPGGGGNGDFEEIPEEYL

Routes

Compare in workbench Download release API JSON

Length
20 aa
Monoisotopic mass
2179.0 Da
Net charge @ pH 7.4
-4.00
Isoelectric point
3.67
GRAVY
-0.985

Coveragecounts only · not riskATLPC0035832

Measurements
2
Endpoints
2
Domains
2/5
Products
1

No matrix stability evidence
1 clearance measurement
1 immunogenicity context entries
2 liability motifs

Jump to domain

Open the matching evidence section below

All evidence index · 2

Exposure / Absorption

No evidence

Distribution / Barrier

1 measurement

Metabolic & Proteolytic Stability

No evidence

Excretion / Persistence

1 measurement

Toxicity / Safety

No evidence

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

Identity summaryCanonical sequence only

Identity status: Canonical sequence only
Residues: 20
Peptidoform features: 0
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0038974	—	4	—	1	2

Residue view

Residue display

20 residues

F1P2R3P4G5G6G7G8N9G10D11F12E13E14I15P16E17E18Y19L20

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

FPRPGGGGNGDFEEIPEEYL

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached

3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modifications1 signal

Feature	Positions	Interpretation	Link
Form-level topology	ATLPF0038974	Open-chain form. Residue-level connection endpoints are shown separately when available.	Not linked

Physicochemical profile

10 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors20 aa · pI 3.7 · GRAVY -0.98

Length: 20 aa
Monoisotopic mass: 2178.99 Da
Average mass: 2180.31 Da
Net charge at pH 7.4: -4.00
Estimated pI: 3.67
GRAVY: -0.985
KD-positive residues: 20.0%
Aromatic residues: 15.0%

Developability interpretation

Ionization context: pH 7.4 separated from pI
Hydrophobicity balance: Leans hydrophilic
Amphipathic moment (μH): 0.87
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

1.93

pH 5

-3.44

pH 6

-3.94

pH 7.4

-4.06

pH 9

-4.79

pH 12

-6.23

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Acidic (D,E)

5 · 25.0%

Basic (K,R,H)

1 · 5.0%

Polar uncharged (N,Q,S,T)

1 · 5.0%

Hydrophobic aliphatic (A,V,I,L,M)

2 · 10.0%

Aromatic (F,W,Y)

3 · 15.0%

Conformational / sulfur (G,P,C)

8 · 40.0%

Top residues

G525.0%E420.0%P315.0%F210.0%R15.0%N15.0%D15.0%I15.0%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

14-20

EIPEEYL

GRAVY -0.729

Most hydrophilic window

13-19

EEIPEEY

GRAVY -1.771

14 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

12 aa window

6-17

GGGNGDFEEIPE

μH 1.11 · charge -4.0

15 aa window

1-15

FPRPGGGGNGDFEEI

μH 1.07 · charge -2.0

18 aa window

1-18

FPRPGGGGNGDFEEIPEE

μH 1.06 · charge -4.0

12 aa window

7-18

GGNGDFEEIPEE

μH 1.06 · charge -5.0

15 aa window

3-17

RPGGGGNGDFEEIPE

μH 1.04 · charge -3.0

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Asn deamidation motif

NG · pos 9

Asn followed by small/polar residues is a known sequence context to review for deamidation susceptibility.

Pro/Gly-rich sequence

P/G · pos 2, 4, 5, 6, 7, 8 +2

High Pro/Gly content can affect local flexibility and secondary-structure propensity.

Alpha-helix amphipathic projection

Helical wheel · Edmundson projection

μ_H = 0.87100°/residue · 20 aa

Hydrophobic moment0.87

Mean K-D hydropathy-0.99

Approx. net charge-4

Projection angle100° / residue

The pale sector marks the direction of the hydrophobic face inferred from μ_H. This is a projection assumption, not a measured fold.

HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμ_H arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μ_H arrow indicates an amphipathic helix, common in antimicrobial peptides.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index

39.00

Instability index

77.5

Above 40 — predicted unstable in vitro.

Boman index

1.86 kcal/mol

Molar extinction coefficient (280 nm)

1,490 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 0.68

Structure-derived (developability)

Computed from the representative peptidoform's chemical structure. Rule-of-5 / beyond-Ro5 framing per Lipinski/Doak.

Topological polar surface area

901.6 Å²

Computed logP (Crippen)

-8.12

Computed logP — distinct from the measured logD endpoint.

Hydrogen-bond donors

Hydrogen-bond acceptors

Rotatable bonds

Rule-of-5 / beyond-Ro5 flags

Beyond bRo5

3 Ro5 violations · MW 2,180.32 Da

Distribution / Barrier

1 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeVd

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Vd1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	0.1 L/kg	Eligible when experimental context matches	human · plasma	Result: Reported point value · Molecular form: ATLPF0038974 · Route: intravenous · Time: steady state · Source: Primary reference linked	Reference

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

cell monolayer

BBB

barrier evidence

Excretion / Persistence

1 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeClearance

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Clearance1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	~ 3.4 mL/min/kg	Eligible when experimental context matches	human · plasma	Result: Approximate quantitative measurement · Molecular form: ATLPF0038974 · Route: intravenous · Source: Primary reference linked	Reference

Evidence landscape

2 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

0 evidence records

Distribution / Barrier

1 evidence record

Metabolic & Proteolytic Stability

0 evidence records

Excretion / Persistence

1 evidence record

Toxicity / Safety

0 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Clearance

Volume Of Distribution

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReference

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Excretion / Persistence Persistence	Clearance	~ 3.4 mL/min/kg	Approximate quantitative measurement	Eligible when experimental context matches	human · plasma	Route: intravenous	Reference Primary reference linked
2	Distribution / Barrier Distribution	Volume Of Distribution	0.1 L/kg	Reported point value	Eligible when experimental context matches	human · plasma	Route: intravenous · Time: steady state	Reference Primary reference linked

1–2 / 2

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

Summary1 linked product

Linked products: 1
Label context: None
Clinical trials: 25
Safety label cues: None

Linked products1 shown

Bivalirudin

Peptide-product match

Reviewed peptide match

Route / product class

Intravenous infusion · Antithrombins

Clinical context

25 trial records · 15 exact intervention matches · 4 with results · latest 2026-04-06

Label safety context

No label safety cue linked

View product

Identity & reference map

2 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary1 reference group

Identity type: canonical sequence
Reported notation: 0
Reference groups: 1
Measurements: 2
ATL peptide ID: ATLPC0035832

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 2

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 2

Different notation

Reported notation does not resolve to the current display sequence.

0 / 2

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

2 / 2

Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity

FPRPGGGGNGDFEEIPEEYL

Reported names

No distinct human-readable aliases are exposed.

Reference map1 reference group

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	DistributionPersistence Clearance, Volume Of Distribution	No reported alias	2 identity 2 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0035832
Identity type: canonical sequence
ADMET endpoints: 2
Evidence records: 2
Reference groups: 1
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0035832

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0035832' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0038974

—

Feature

Positions

Interpretation

Link

Form-level topology

ATLPF0038974

Open-chain form. Residue-level connection endpoints are shown separately when available.

Not linked

Value

Analysis use

Assay / model

Result context

Reference

0.1 L/kg

Eligible when experimental context matches

human · plasma

Result: Reported point value · Molecular form: ATLPF0038974 · Route: intravenous · Time: steady state · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

~ 3.4 mL/min/kg

Eligible when experimental context matches

human · plasma

Result: Approximate quantitative measurement · Molecular form: ATLPF0038974 · Route: intravenous · Source: Primary reference linked

Reference

ADMET domain

Endpoint

Reported value

Result type

Analysis use

Assay / model

Condition

Reference

Excretion / Persistence

Persistence

Clearance

~ 3.4 mL/min/kg

Approximate quantitative measurement

Eligible when experimental context matches

human · plasma

Route: intravenous

Reference

Primary reference linked

Distribution / Barrier

Distribution

Volume Of Distribution

0.1 L/kg

Reported point value

Eligible when experimental context matches

human · plasma

Route: intravenous · Time: steady state

Reference

Primary reference linked

Reference

Supports

Reported identity

Records

Reference

Open

DistributionPersistence

Clearance, Volume Of Distribution

No reported alias

2 identity

2 evidence